申请人:MERCK SHARP & DOHME
公开号:WO2021127460A1
公开(公告)日:2021-06-24
Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein A, A1, A2, R1, R2 and R3 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
揭示了化合物的结构式(I),或其药用盐:(I)其中A,A1,A2,R1,R2和R3如本文所定义,这些化合物具有拮抗PCSK9的属性。还描述了包含结构式I的化合物或其盐的制药配方,以及治疗心血管疾病和与PCSK9活性相关的疾病的方法,例如动脉粥样硬化,高胆固醇血症,冠心病,代谢综合征,急性冠状综合征或相关心血管疾病和心脏代谢疾病的条件。